Vernalis Hunts For An In-Licensing Deal Or Acquisition In CNS/Oncology
This article was originally published in The Pink Sheet Daily
Analysts believe Vernalis now is in a "fairly secure" cash position to license or acquire an earlier-stage compound.
You may also be interested in...
Vernalis reveals new strategy to market long-acting prescription cough/cold preparations in the US, supported by Tris Pharma's technology and a $104 million fundraising
Roche primary care "scale up": Ahead of a potential launch of the GLP-1 analog taspoglutide for the treatment of type 2 diabetes, Roche will need to "scale up" its primary care infrastructure, Pharmaceuticals Chief Operating Officer Pascal Soriot said during an investor meeting in New York Feb. 4. If approved, the drug would compete against entrenched rivals, including Lilly/Amylin's established Byetta (exenatide) and Novo Nordisk's recently approved Victoza (liraglutide). Still, Soriot maintained, "the scale-up is not as big as people ultimately think." In the U.S., the company already has a primary care infrastructure in place, he said, including 570 reps visiting physician offices and 250 visiting clinics. The filing for taspoglutide has been pushed back to 2011 from an earlier target of 2010 due to a delay in the start of a large cardiovascular safety study, T-EMERGE 8. Roche is expecting to file once interim results are in hand
UK biotech gets $6 million upfront, half of which is structured as an equity investment by GSK.